Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Acad Nutr Diet ; 124(3): 387-396.e5, 2024 03.
Article in English | MEDLINE | ID: mdl-38441080

ABSTRACT

BACKGROUND: An inverse relationship between vitamin D supplementation and C-reactive protein (CRP) and hypertension has been reported, mostly through observational data. This inverse relationship, however, has not been confirmed in randomized controlled trials (RCTs). A meta-analysis of RCTs is needed to provide more robust evidence. OBJECTIVE: This systematic review of RCTs was conducted to assess the effect of vitamin D supplementation on CRP, systolic blood pressure (SBP), and diastolic blood pressure (DBP) in postmenopausal women. METHODS: Four databases (PubMed, Web of Science, Embase, and Scopus) were systemically searched to identify relevant RCTs published in international scientific journals up to January 2023. Changes from baseline and SDs of CRP, SBP, and DBP were compared between postmenopausal women who received vitamin D supplementation and those who did not (controls). These parameters were applied to compute the overall effect sizes using the random-effects model. Data were summarized as mean difference (MD) with 95% CI. Heterogeneity among arms was scrutinized using the Cochrane's Q test and I2 statistic. Publication bias was judged by means of funnel plots and Egger's test. RESULTS: Seven studies with 6 arms on CRP, 6 arms on SBP, and 6 arms on DBP were included in the meta-analysis. Combined effect sizes suggested a significant effect of vitamin D supplementation on CRP (MD = -0.65 mg/L; 95% CI -0.93 to -0.37 mg/L; P < .001). In addition, CRP concentrations were significantly reduced after vitamin D supplementation in studies with a duration of more than 3 months (MD = -0.91 mg/L; 95% CI -1.37 to -0.45 mg/L; P < .001) and studies involving doses of ≤1,000 IU/d (MD = -2.10 mg/L; 95% CI -2.51 to -1.68 mg/L; P < .001). Vitamin D supplementation did not reduce SBP significantly (MD = -1.06 mm Hg; 95% CI -2.43 to 0.30 mm Hg; P = .127) and DBP (MD = 0.003 mm Hg; 95% CI -0.86 to 0.86 mm Hg; P = .994) levels compared with control groups. CONCLUSIONS: This meta-analysis concluded that vitamin D supplementation is associated with reduced CRP concentrations among postmenopausal women.


Subject(s)
C-Reactive Protein , Postmenopause , Female , Humans , Blood Pressure , Randomized Controlled Trials as Topic , Dietary Supplements , Vitamin D
2.
J Nutr Sci ; 13: e3, 2024.
Article in English | MEDLINE | ID: mdl-38282652

ABSTRACT

Cardiovascular disease (CVD) is one of the most important diseases which controlling its related risk factors, such as metabolic and inflammatory biomarkers, is necessary because of the increased mortality risk of that. The aim of our meta-analysis is to reveal the general effect of vitamin K supplementation on its related risk factors. Original databases were searched using standard keywords to identify all randomized clinical trials (RCTs) investigating the effects of vitamin K on CVD. Pooled weighted mean difference (WMD) and 95 % confidence intervals (95 % CI) were achieved by random-model effect analysis for the best estimation of outcomes. The statistical heterogeneity was determined using the Cochran's Q test and I2 statistics. Seventeen studies were included in this systematic review and meta-analysis. The pooled findings showed that vitamin K supplementation can reduce homeostatic model assessment insulin resistance (HOMA-IR) (WMD: -0⋅24, 95 % CI: -0⋅49, -0⋅02, P = 0⋅047) significantly compared to the placebo group. However, no significant effect was observed on other outcomes. Subgroup analysis showed a significant effect of vitamin K2 supplementation compared to vitamin K1 supplementation on HOMA-IR. However, no significant effect was observed on other variables. Also, subgroup analysis showed no potential effect of vitamin K supplementation on any outcome and omitting any articles did not affect the final results. We demonstrated that supplementation with vitamin K has no effect on anthropometrics indexes, CRP, glucose metabolism, and lipid profile factors except HOMA-IR.


Subject(s)
Cardiovascular Diseases , Insulin Resistance , Humans , Dietary Supplements , Vitamin K , Blood Glucose/metabolism , Cardiovascular Diseases/prevention & control
3.
Diabetes Res Clin Pract ; 209: 111073, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38142749

ABSTRACT

BACKGROUND: The effect of MPA on the lipid profile and CVD risk is still controversial; hence, this comprehensive dose-response meta-analysis of randomized controlled trials was conducted to assess the effect of MPA on lipid profiles in women. METHODS: A comprehensive search was conducted in the following databases: Web of Science, Scopus, PubMed/Medline, and Embase, up to October 20, 2023. A random-effects meta-analysis approach based on the DerSimonian and Laird method was used to compute the combined estimates of the intervention's impact on the lipid profile. RESULTS: 35 eligible studies with 58 arms were included in our meta-analyses analysis. Combined effect sizes suggested a significant effect of MPA on total cholesterol (TC) levels (WMD: -3.43 mg/dL, 95 % CI: -5.38 to -1.48, p < 0.001), HDL-C levels (WMD: -3.34 mg/dL, 95 % CI: -3.77 to -2.91, p < 0.001), and triglyceride (TG) levels (WMD: -9.13 mg/dL, 95 % CI: -10.92 to -7.33, p < 0.001). The subgroup meta-analysis revealed a more substantial reduction in TC in studies with dosages > 2.5 mg/day (WMD: -4.10 mg/dL), mean participant age lower than 60 years (WMD: -3.80 mg/dL), mean BMI lower than 25 kg/m2 (WMD: -5.61 mg/dL), duration of intervention of 12 months or more (WMD: -3.98 mg/dL), and when the baseline TC value was equal to or greater than 200 mg/dL (WMD: -4.13 mg/dL). CONCLUSIONS: The current meta-analysis showed a statistically significant decrease in TC, TG, and HDL-C levels and a non-significant increase in LDL-C levels after MPA administration in women.


Subject(s)
Lipids , Medroxyprogesterone Acetate , Randomized Controlled Trials as Topic , Humans , Female , Lipids/blood , Medroxyprogesterone Acetate/administration & dosage , Triglycerides/blood , Dose-Response Relationship, Drug , Cholesterol, HDL/blood , Cholesterol/blood , Middle Aged , Cholesterol, LDL/blood
4.
Eur J Obstet Gynecol Reprod Biol ; 287: 176-185, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37364427

ABSTRACT

OBJECTIVE: Little evidence exists on the effect of 17beta-estradiol plus norethisterone acetate on all the anthropometric indices. Hence, this systematic review and meta-analysis of Randomized Controlled Trials was conducted to give an evidence-based report on the effect of 17beta-estradiol plus norethisterone acetate on anthropometric indices. METHODS: The literature search was executed in databases including PubMed/Medline, Web of Science, Scopus, Embase, and Google Scholar to recognize clinical trials that examined the influence of 17beta-estradiol plus norethisterone acetate on obesity indices from database inception to Jan 2023. RESULTS: Combined findings were generated from 20 eligible articles. The meta-analysis showed that body weight (Weighted Mean Difference (WMD): -0.47 kg, 95% CI: -1.32, 0.37, p = 0.274), body fat (WMD: 0.16 kg, 95% CI: -1.26, 1.59, p = 0.821), WHR (WMD: 0.001 kg, 95% CI: -0.006, 1.15, p = 0.872), and LBM (WMD: -0.02 kg, 95% CI: -1.19, 1.15, p = 0.970) were not modified in DHEA group compared to the control, but BMI levels were significantly reduced in 17beta-estradiol plus norethisterone acetate group (WMD: -0.15 kg/m2, 95% CI: -0.30, -0.008, p = 0.039). Moreover, based on intervention duration (months), a more significant reduction in BMI was found in trials that were performed on studies with ˃3 months duration (WMD: -0.176 kg/m2) than studies with ≤ 3 months (WMD: 0.05 kg/m2). CONCLUSION: Administration of 17beta-estradiol plus norethisterone acetate for more than 3 months results in a decrease in BMI, which helps to reduce cardiovascular disease risk.


Subject(s)
Estradiol , Obesity , Humans , Norethindrone Acetate , Randomized Controlled Trials as Topic , Body Weight , Dietary Supplements/analysis
5.
J Biochem Mol Toxicol ; 34(12): e22586, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32711406

ABSTRACT

Apoptosis is an important process of cell death that controls the intrinsic and extrinsic pathways. Syringic acid (SRA)-a phenolic compound well-known in traditional Indian Ayurvedic medicine-has been reported to suppress cell proliferation of various cancer cells. Therefore, the current study aimed to investigate the inhibitory role of SRA on the proliferation of oral squamous cell carcinoma cells (SCC131) via reactive oxygen species (ROS) and induced mitochondria-mediated apoptosis. The study results showed that SRA (IC50 ) was able to induce apoptosis in SCC131 cells via increased ROS generation, alteration of mitochondrial membrane potential, nuclear fragmentation, apoptotic morphological differences, and DNA injury. Moreover, SRA inhibited proliferative markers such as proliferating cell nuclear antigen and cyclin D1 protein expression in SCC131 cells. A diminished level of B-cell lymphoma 2 (Bcl-2) and augmented level of Bcl-2-associated X protein (Bax) were considered as markers of apoptotic cell death. In addition, SRA was able to decrease Bcl-2 and increase mutant p53, caspase-9, Bax, and caspase-3 expression in SCC131 cells. Taken together, SRA succeeded in inhibiting SCC131 cell growth through the ROS and mitochondria-mediated apoptosis in oral cancer cells.

6.
Biomed Pharmacother ; 84: 430-437, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27682737

ABSTRACT

Solanum xanthocarpum Schrad. & Wendl, is a traditional edible leaves as a form of decoction, extracts used as a herbal medicine, and consumed for health promoting profiles. The present investigation was carried out to evaluate antioxidant status and lipid peroxidation level of anticancer activity of Solanum xanthocarpum (SXC) on Diethylnitrosamine (DEN) induced hepato carcinogenesis in male Wistar albino rats. Hepatic cancer was developed on the liver of Wistar rats treated by DEN or vehicle three times a week for 16 weeks. Tumour incidence, tumour volume, tumour burden, lipid peroxidation, antioxidant, liver marker enzymes and histopathological changes were assessed in DEN alone and in DEN+SXC leaves extract treated rats. Hundred percent tumour incidences with an imbalance in carcinogen metabolizing enzymes and cellular redox status were observed in rats treated with DEN alone. Oral administration of SXC aqueous leaves extract treatment at a dose of 150mg/kg b.w. to DEN treated rats were prevented tumour incidence and restored the elevated activities of liver marker enzymes and antioxidant status to near normal with decreased lipid peroxide levels. The biochemical consistent with histopathological observations suggesting marked hepatoprotective effect of the leaves extract in a dose dependent manner. These results clearly suggest that SXC aqueous leaves extract treatment prevents liver damage, lipid peroxidation, protects the antioxidant defense system and anti-carcinogenic potential in DEN induced hepatic carcinogenesis.


Subject(s)
Antioxidants/pharmacology , Carcinogenesis/pathology , Lipid Peroxidation/drug effects , Liver Neoplasms/drug therapy , Plant Extracts/therapeutic use , Plant Leaves/chemistry , Solanum/chemistry , Animals , Biomarkers, Tumor/metabolism , Body Weight/drug effects , Diethylnitrosamine , Liver/drug effects , Liver/enzymology , Liver/pathology , Liver Neoplasms/blood , Liver Neoplasms/chemically induced , Liver Neoplasms/metabolism , Male , Organ Size , Oxidative Stress/drug effects , Plant Extracts/pharmacology , Rats, Wistar , Thiobarbituric Acid Reactive Substances/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL